YolTech Therapeutics

What YolTech Therapeutics does

YolTech Therapeutics (Chinese name: 尧唐生物; legal entity: Shanghai Yaotang Biotechnology Co., Ltd., 上海尧唐生物科技股份有限公司) is a privately held, late clinical-stage biotechnology company founded in 2021 by Dr. Yuxuan Wu and Dr. Zi Jun (Emma) Wang, headquartered in Shanghai's Minhang District with a GMP manufacturing facility in Nanjing. The company develops in vivo gene editing therapies delivered via proprietary lipid nanoparticles (LNPs) and mRNA, targeting serious genetic, metabolic, and cardiovascular diseases. Its clinical pipeline comprises six programs: YOLT-201 (ATTR amyloidosis; China's first LNP-mediated in vivo gene editing therapy to enter clinical development; NMPA-cleared March 2024), YOLT-202 (AATD; FDA IND-cleared March 2026 for Phase 2/3 with RMAT and Orphan Drug designations), YOLT-203 (PH1; FDA IND-cleared November 2025 with RMAT, Orphan Drug, Rare Pediatric Disease, and EMA Orphan Drug designations), YOLT-101 (HeFH; FDA and NMPA IND-cleared with 24-week Nature Medicine data showing 52.3% LDL-C reduction), YOLT-204 (Beta Thalassemia/SCD), and YOLT-102 (ASCVD targeting LP(a)), plus earlier-stage programs including in vivo CAR-T YOLT-401 for autoimmune disease.

The company's technology foundation rests on three integrated proprietary platforms: the HEPDONE™ AI-powered, metagenomics-driven high-throughput evolution platform (50TB base pairs, 311K samples, 21B proteins, 1M Cas enzymes, throughput of 10B+ per round) for de novo editor discovery; the YolBE® adenine base editor family (including hpABE5, with deaminase derived from Hafnia paralvei) and YolCas™/YolCas12™ (Cas12HF) CRISPR editors; and the YOL-LNPs® proprietary lipid library of thousands of novel ionizable cationic lipids with claimed up to 5x stronger delivery rates than international counterparts to both liver and non-liver organs (spleen, bone marrow). YolTech has been granted multiple patents covering base editing, CRISPR/Cas systems, LNP technology, and DNA editing systems, with 80+ patent applications filed. End-to-end GMP manufacturing (mRNA synthesis, LNP encapsulation, aseptic fill-finish) at the Nanjing facility, expanding to approximately 54,000 sq ft, supports commercial readiness.

YolTech operates a hybrid business model combining geographic out-licensing with retained direct commercialization rights. China rights to YOLT-101 are licensed to Salubris (RMB ~1B deal value, August 2024); worldwide ex-Greater China rights to SERP-01/YOLT-202 are licensed to Serapha Bio (June 2026, milestone potential exceeding $2B plus undisclosed upfront and minority equity stake). YolTech retains global rights for YOLT-201 (ATTR), YOLT-203 (PH1), YOLT-204 (SCD/Beta Thalassemia), YOLT-102 (ASCVD), and earlier-stage programs, with planned direct commercialization supported by multiregional clinical trials (MRCTs) in the U.S. and other countries. Cumulative funding of approximately $144.85M has been raised across five venture rounds (Series C $73.8M in May 2026 led by Loyal Valley Capital; Series B ~$42.1M in September 2025 led by AstraZeneca-CICC; Series A+ ~$14.1M in November 2023 led by Decheng Capital). The company is pre-revenue with a one-time gene-editing therapy value-based pricing model intended upon commercial launch.

Name

YolTech Therapeutics

Legal name

Shanghai Yaotang Biotechnology Co., Ltd. (上海尧唐生物科技股份有限公司)

Website

https://yoltx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Clinical-stage Chinese biotechnology company developing in vivo gene editing therapies via proprietary LNP-mRNA delivery and base editors (YolBE®), targeting genetic, metabolic, and cardiovascular diseases including ATTR, AATD, PH1, and HeFH.

Ownership category

akta.pro rank

Product category

In vivo gene editing therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG), Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)

Keywords

• In vivo gene editing
• Lipid nanoparticle delivery
• CRISPR base editing
• Genetic disease therapeutics
• MRNA-LNP drugs

Headquarters

HQ city

Minhang

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Licensing & Royalty Income: Geographic out-licensing of pipeline assets (e.g., YOLT-101 China rights to Salubris; SERP-01/YOLT-202 ex-Greater China rights to Serapha in connection with $230M reverse merger, with milestone potential exceeding $2 billion). Generates upfront payments, milestone payments, and royalties.
2. Future Direct Product Sales (Planned): Pre-revenue clinical-stage company. Future revenue anticipated from commercialization of one-time gene-editing therapies (YOLT-201, YOLT-202, YOLT-203, YOLT-101, etc.) globally; supported by ~$130M+ raised to advance clinical pipeline and commercial readiness.
3. Equity Financing (Capital Raise): Multi-round venture financing (Series A+ $15M led by Decheng Capital, Series B $45M led by AstraZeneca-CICC, Series C $70M led by Loyal Valley Capital) totaling approximately $130M+ to fund clinical pipeline advancement and global expansion.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Core offering

YolTech Therapeutics develops in vivo gene editing therapeutic candidates delivered via proprietary lipid nanoparticles (LNPs) for one-time treatment of serious genetic, metabolic, cardiovascular, and rare diseases. Its offering combines two proprietary technology platforms — the HEPDONE™ AI-powered metagenomics-driven editor discovery platform (producing the YolBE® base editor and YolCas™ CRISPR-Cas systems) and the YOL-LNPs® lipid nanoparticle delivery platform — with a clinical-stage pipeline that includes YOLT-201 (ATTR), YOLT-202 (AATD), YOLT-203 (PH1), YOLT-204 (SCD/Beta Thalassemia), YOLT-101 (FH), and YOLT-102 (ASCVD).

Product overview

YolTech Therapeutics is a clinical-stage biotechnology company whose offering is a platform-plus-pipeline architecture rather than a single product. The platform foundation consists of two integrated core technology platforms: the HEPDONE™ Novel Editor Platform (an AI-powered, metagenomics-driven high-throughput evolution platform that generates proprietary editors such as the YolBE® adenine base editor family including hpABE5 and the YolCas™/YolCas12™ CRISPR-Cas editors) and the proprietary YOL-LNPs® LNP Delivery Platform (in-house lipid library, screening, and GMP manufacturing). These platforms together produce and deliver a clinical-stage pipeline of in vivo gene editing therapeutic candidates: YOLT-201 (ATTR/ATTR-CM, LNP-CRISPR-Cas9), YOLT-202 (AATD, in vivo base editing), YOLT-203 (PH1, YolCas12™-based), YOLT-204 (Beta Thalassemia/Sickle Cell Disease), YOLT-101 (HeFH, in vivo base editing using hpABE5), YOLT-102 (ASCVD, targeting LP(a)), plus earlier-stage programs YOLT-205, YOLT-206, YOLT-103, and the in vivo CAR-T program YOLT-401 for autoimmune disease.

Differentiator

Problem solved

Functional benefit

Brands

• HEPDONE™: High-Throughput Evolution Platform for Discovery and Optimization of Novel Editors — proprietary AI-powered metagenomics-based platform used to discover and evolve YolTech's proprietary editors (YTDE, YolBE).
• YolBE®
• YOL-LNPs®
• YolCas™

Products and services

• YOLT-101 Investigational in vivo base editing therapy for heterozygous familial hypercholesterolemia (HeFH) using YolTech's proprietary hpABE5 adenine base editor (a nCas9 fused with a deaminase derived from Hafnia paralvei) delivered via lipid nanoparticle (LNP) to edit the PCSK9 gene in hepatocytes and durably lower LDL-C. At 0.6 mg/kg, YOLT-101 reduced circulating PCSK9 by 74.4% and LDL-C by 52.3% at Week 24 (Nature Medicine, 2026). Salubris holds China rights; YolTech retains ex-China rights.
• YOLT-202 (SERP-01) Investigational in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD) that corrects the PiZ mutation (SERPINA1 Glu342Lys) back to PiM using YolTech's proprietary adenine base editor delivered via LNP; engineered for on-target editing with minimal bystander activity. Interim IIT data showed rapid, dose-dependent increases in AAT levels reaching the protective threshold of 11 µM and the normal range (>20 µM) at 45 mg with >95% corrected M-AAT proteins. Granted FDA Orphan Drug Designation and RMAT Designation.
• YOLT-201 Investigational in vivo CRISPR-Cas9 gene editing therapy using LNP-mRNA delivery to edit the TTR gene in hepatocytes for permanent reduction of serum transthyretin (TTR) protein, with the goal of one-time lifelong treatment of Transthyretin Amyloidosis (ATTR/ATTR-CM). High-dose cohort achieved ~90% sustained serum TTR knockdown; patients receiving a second dose approached near-complete TTR elimination (~100%). First LNP-mediated in vivo gene editing therapy approved for clinical trials in China.
• YOLT-203 Investigational in vivo CRISPR gene editing therapy for Primary Hyperoxaluria Type 1 (PH1) using YolTech's proprietary Cas12HF (YolCas12™) system delivered via lipid nanoparticle (LNP) to edit the HAO1 gene in the liver and reduce oxalate production. Demonstrated ~70% reduction in urinary oxalate levels in PH1 patients. Granted FDA Orphan Drug Designation, Rare Pediatric Disease Designation, RMAT Designation, and EMA Orphan Drug Designation.
• YOLT-204 Investigational in vivo gene editing therapy for Beta Thalassemia and Sickle Cell Disease (SCD) using mRNA-LNP delivery to hematopoietic stem cells, enabling treatment of inherited blood disorders without ex vivo manipulation. Listed under ClinicalTrials.gov (NCT06678165).
• YOLT-102 Investigational in vivo gene editing therapy targeting LP(a) for Atherosclerotic Cardiovascular Disease (ASCVD) to enable sustained reduction of LP(a) and cardiovascular risk from a single dose.
• YOLT-401 (In vivo CAR-T program) Early-stage in vivo CAR-T program targeting autoimmune diseases via in vivo CAR-T approach to overcome limitations of ex vivo CAR-T manufacturing. Currently in lead optimization stage.

Quantifiable outcome

• LDL-C reduced by 52.3% at Week 24 in 0.6 mg/kg cohort of YOLT-101 (HeFH patients); PCSK9 reduced by 74.4%
• +9 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered flagship licensing partner (ex-greater china rights to serp-01/yolt-202), counterparty in licensing + reverse merger transaction, strategic r&d collaboration partner, major licensing partner (china rights for yolt-101), industry licensing partner (agriculture applications), distribution partner (crispr tools in greater china) and clinical research partner (iit).

• Serapha Bio (Nasdaq: AATD, formed via merger with Boundless Bio)flagship licensing partner (ex-greater china rights to serp-01/yolt-202)OEM/ Whitelabel/ Licensing Partner · 24 June 2026Concurrent with Serapha's licensing agreement with YolTech, Serapha entered a reverse merger with Boundless Bio to trade on Nasdaq under ticker AATD with $230M in private placement financing co-led by RA Capital Management and RTW Investments. Licensing agreement grants Serapha worldwide rights (outside Greater China) to SERP-01/YOLT-202 in exchange for undisclosed upfront payment and minority equity stake. Milestone potential exceeding $2 billion. Combined company cash expected to fund operations into H2 2029, supporting Phase 2 completion and Phase 3 initiation.
• Boundless Bio (Nasdaq: BOLD pre-merger)counterparty in licensing + reverse merger transactionStrategic or Co-development Partner · 23 June 2026Boundless Bio entered into a definitive all-stock merger agreement with Serapha Bio; combined company operates under Serapha Bio name on Nasdaq under ticker AATD. Pre-merger Boundless Bio investors received 3.7% share plus $44-48 million cash dividend. Boundless Bio was a 2023 Fierce 15 winner abandoning cancer asset BBI-940. Transaction expected to close Q4 2026.
• Crystal Technology (晶泰科技)strategic r&d collaboration partnerStrategic or Co-development Partner · 23 February 2026AI-assisted mRNA drug R&D collaboration announced February 23, 2026. Leverages Crystal Technology's AI/machine learning capabilities to accelerate YolTech's mRNA-based gene editing therapeutic development.
• Salubris (深圳信立泰)major licensing partner (china rights for yolt-101)OEM/ Whitelabel/ Licensing Partner · 27 August 2024Licensing agreement announced August 27, 2024 granting Salubris China-side commercial rights for YOLT-101, YolTech's in vivo base editing therapy targeting PCSK9 for treatment of Familial Hypercholesterolemia. Deal valued at approximately RMB 1 billion (10亿元). Ex-China rights retained by YolTech.
• Wimi Bio (未米生物)industry licensing partner (agriculture applications)OEM/ Whitelabel/ Licensing Partner · 27 June 2024Licensing partnership for YolTech's proprietary high-activity Cas enzyme to advance gene editing technology applications in agriculture. Expands YolTech's gene editing IP into non-therapeutic verticals.
• KACTUS (恺佧生物)distribution partner (crispr tools in greater china)Channel Partner/ Reseller/ Distributor · 21 June 2024Licensing partnership to commercialize YolTech's novel CRISPR/Cas gene editing tool YolCas12™ in Greater China. Supports distribution of proprietary gene editing tools to research market.
• Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine (上海交通大学医学院附属仁济医院)clinical research partner (iit)Implementation/ SI/ Consulting PartnerPartner for investigator-initiated trial (IIT) of YOLT-101 (NCT06458010) for treatment of heterozygous familial hypercholesterolemia (HeFH). Single-center, open-label dose escalation study. Co-investigators include Academician Xia Qiang and Dr. Yang Taihua of Renji Hospital. Co-authored YOLT-101 clinical data publication on medRxiv.

Scale indicators16 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• CRISPR Therapeutics: Clinical-stage gene editing company developing CRISPR/Cas9-based therapeutics including Casgevy (approved for sickle cell disease and beta-thalassemia) — directly comparable to YolTech in vivo gene editing approach and target indications including hemoglobin disorders.
• Intellia Therapeutics: Leading in vivo CRISPR/Cas9 gene editing company with clinical programs in ATTR (NTLA-2001, comparable to YOLT-201) and HAE — directly competing in the same in vivo editing modality and several of the same indications.
• Beam Therapeutics: Pioneer in base editing technology with clinical programs in sickle cell disease and other genetic diseases — directly comparable to YolTech's YolBE/hpABE5 base editor approach and in vivo delivery ambitions.
• Verve Therapeutics: Clinical-stage company developing in vivo base editing therapies for cardiovascular disease, with VERVE-101 (PCSK9) directly comparable to YolTech's YOLT-101 — same target, same editing approach, same indication.
• Editas Medicine: Clinical-stage CRISPR gene editing company with programs in sickle cell disease, beta-thalassemia, and other genetic diseases — directly comparable to YolTech's pipeline approach using CRISPR-based editors.
• Sangamo Therapeutics: Clinical-stage gene editing and gene therapy company with programs in ATTR and other rare diseases — directly comparable in vivo editing modality and overlapping indications with YolTech.

Emerging players

• Prime Medicine: Clinical-stage prime editing company developing next-generation gene editing therapies — comparable emerging modality in the precision gene editing space, with overlapping target disease areas.
• Korro Bio: Clinical-stage RNA editing company developing oligonucleotide-based ADAR-mediated editing — adjacent modality to YolTech's base editing approach, both targeting genetic diseases with single-administration therapies.

Broad incumbents

• Moderna: Established mRNA-LNP delivery leader; YolTech's YOL-LNPs platform builds on the same lipid nanoparticle delivery modality pioneered by Moderna, providing shared technology infrastructure and competitive context.
• BioNTech: Major mRNA-LNP company with growing gene editing ambitions through partnerships; directly comparable LNP delivery technology and expanding pipeline into in vivo gene editing therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/yoltech-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about YolTech Therapeutics